Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-20T03:43:42.210Z Has data issue: false hasContentIssue false
  • English
  • Français

Policy implications of rationalization of statin use in Lithuania

Published online by Cambridge University Press:  21 July 2009

Edmundas Kadusevicius ,
Danguole Jankauskiene ,
Inga Paulauskaite  and
Rimvydas Slapikas
Edmundas Kadusevicius
Affiliation:
Kaunas University of Medicine
Danguole Jankauskiene
Affiliation:
Mykolas Romeris University
Inga Paulauskaite
Affiliation:
Kaunas University of Medicine
Rimvydas Slapikas
Affiliation:
Kaunas University of Medicine
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The aim of this study was to assess the trends and costs of statin use in Lithuania over a 3-year period and perform a cost-minimization and reference price analysis to rationalize the use of financial resources of the National Health Care System.

Methods: The defined daily dose (DDD) methodology was applied for assessment of statin use, which was expressed in DDD/1,000 inhabitants/day. Cost minimization and reference price calculations were used in the economic analysis.

Results: Over the 3-year period (2005–2007), the consumption and expenditures of statins in Lithuania doubled. The consumption went up from 3.87 DDD/1,000 inhabitants/day (in 2005) to 8.35 DDD/1,000 inhabitants/day (in 2007). Total expenses of statins increased during the same period from LTL6.186 million in 2005 to LTL12.418 million in 2007. Approximately 68 percent of the estimated costs for statins in 2007 were for atorvastatin. Provided that the calculated reference prices were fixed, the estimated savings would amount to a minimum of LTL1.371 million per year and could reach yearly savings in the order of LTL3.163 million. The total expenses would drop by at least 11 percent, and the decrease in costs could be as high as 25 percent (€1 = LTL3.4528).

Conclusions: Statins consumption is still very low in Lithuania in comparison with other European Union countries. Implementation of cholesterol education programs and changing reimbursement profile for statins therapy will increase consumption and expenditures. The introduction of reference-based pricing as an indirect cost control policy would help rationalizing the use of statins and their expenditures.

Keywords

StatinsEpidemiologyEconomicsCost minimizationReference price
Type
Research Reports
Information
International Journal of Technology Assessment in Health Care , Volume 25 , Issue 3 , July 2009 , pp. 419 - 424
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Bonita, R, Beaglehole, R, Kjellström, T. Basic epidemiology. 2nd ed. World Health Organization. http://whqlibdoc.who.int/publications/2006/9241547073_eng.pdf (accessed January 24, 2008).Google Scholar
2. Burne, J. Statins: The truth. 2007. http://www.dailymail.co.uk/health/article-432395/Statins-truth.html (accessed March 16, 2008).Google Scholar
3. Danish Medicines Agency. Statistics grouped according to constituents, 2002–2006. http://dkma.medstat.dk/MedStatDataViewer.php (accessed March 16, 2008).Google Scholar
4. Danzon, PM. Reference pricing: Theory and evidence. http://hc.wharton.upenn.edu/danzon/PDF%20files/barcelonaeditfinal%20.pdf (accessed January 28, 2008).Google Scholar
5. Estonian Medical Statistics Bureau. Estonian Statistics on Medicines 2002–2006. http://www.ravimiamet.ee/11880 (accessed March 17, 2008).Google Scholar
6. Hirsch, M, O'Donnell, J, Olsson, A. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Int J Cardiol. 2005;104:251–256.CrossRefGoogle ScholarPubMed
7. Jacobson, TA. Clinical context: Current concepts of coronary heart disease management. Am J Med. 2001;110:3–11.CrossRefGoogle ScholarPubMed
8. Lithuanian Health Information Centre. http://www.lsic.lt (accessed 24 February 24, 2008).Google Scholar
9. National Agency for Medicines, Finland. Drug consumptions statistics. http://www.nam.fi/instancedata/prime_product_julkaisu/laakelaitos/embeds/laakekulutus_2006_Medicines_in_2006.pdf (accessed June 11, 2009)Google Scholar
10. Norwegian Prescription Database. Drug consumption in Norway. http://www.legemiddelforbruk.no/english/ (accessed 16 March 16, 2008).Google Scholar
11. Senes, S, Penm, E. Medicines for cardiovascular health: Are they used appropriately? Australian Institute of Health and Welfare: http://www.aihw.gov.au/publications/cvd/mfchatua/mfchatua-c00.pdf (accessed March 16, 2008).Google Scholar
12. Silva, M, Matthews, ML, Jarvis, C, et al. Meta analysis of drug-induced adverse events associated with intensive dose statin therapy. Clin Ther. 2007;29:253–260.CrossRefGoogle ScholarPubMed
13. Strom, BL. Statins and over-the-counter availability. N Engl J Med. 2005;352:1403–1405.CrossRefGoogle ScholarPubMed
14. The National AIDS Treatment Advocacy Project. UK government backs generic statins: Pravastatin, simvastatin. http://www.natap.org/2007/newsUpdates/010507_07.htm (accessed April 5, 2008).Google Scholar
15. Wilson, AE. De-mystifying pharmacoeconomics. Drug Benefit Trends 2005;11:56–67.Google Scholar
16. WHO Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atcddd/ (accessed October 18, 2008).Google Scholar